Mind Medicine (MindMed) Inc. (MNMD) — MindMed reported third-quarter 2025 results, with R&D expense of about $31.0 million driven by its MM120 (LSD) program.
Management said enrollment across its three pivotal MM120 orally disintegrating tablet trials for anxiety and depression remained on track, with Voyage topline data expected in the first half of 2026 and additional Phase 3 readouts later in 2026. CEO Rob Barrow characterized 2025 as a year of strong execution.
Source: businesswire.com
For the rest of that week's sector news, read our week in review.